2.2500
+0.1000
+(4.65%)
At close: January 28 at 4:00:00 PM EST
2.3600
+0.11
+(4.89%)
After hours: 7:56:25 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 1 | 2 | 3 |
| Avg. Estimate | -0.4 | -0.31 | -1.44 | -1.35 |
| Low Estimate | -0.43 | -0.31 | -1.47 | -1.71 |
| High Estimate | -0.36 | -0.31 | -1.41 | -0.64 |
| Year Ago EPS | -0.28 | -0.34 | -2.7 | -1.44 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | -- | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | -- | 0.00% | 0.00% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.89 | -0.53 | -0.46 | -0.41 |
| EPS Actual | -0.28 | -0.34 | -0.31 | -0.38 |
| Difference | 0.61 | 0.19 | 0.15 | 0.03 |
| Surprise % | 68.41% | 35.53% | 32.90% | 7.80% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.4 | -0.31 | -1.44 | -1.35 |
| 7 Days Ago | -0.43 | 0 | -1.47 | -1.71 |
| 30 Days Ago | -0.43 | 0 | -1.47 | -1.71 |
| 60 Days Ago | -0.43 | 0 | -1.51 | -1.74 |
| 90 Days Ago | -0.43 | 0 | -1.51 | -1.74 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | 1 |
| Up Last 30 Days | 1 | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| UBX | -44.57% | 8.82% | 46.59% | 6.20% |
| S&P 500 | 9.90% | 11.00% | 14.01% | 13.54% |
Upgrades & Downgrades
| Initiated | Chardan Capital: Buy | 1/10/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/15/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/16/2024 |
| Upgrade | Wedbush: Neutral to Outperform | 11/16/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/14/2023 |
Related Tickers
CMPX Compass Therapeutics, Inc.
3.2200
+14.18%
VIGL Vigil Neuroscience, Inc.
2.2100
-2.21%
CHRO Channel Therapeutics Corporation
2.4600
+10.81%
XCUR Exicure, Inc.
11.52
-1.71%
PGEN Precigen, Inc.
1.2700
-2.31%
WINT Windtree Therapeutics, Inc.
0.1418
-10.42%
ERNA Eterna Therapeutics Inc.
0.4400
-0.02%
VERU Veru Inc.
0.5210
-17.97%
ONCO Onconetix, Inc.
0.6000
-6.76%
NEUP Neuphoria Therapeutics Inc.
4.9100
+5.14%